JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jun 28, 2012) - www.StockCall.com offers free research on Abbott Laboratories (NYSE: ABT) and GlaxoSmithKline plc (NYSE: GSK) from the Drug Manufacturers - Major industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.
The drug manufacturers - major industry has been performing relatively well recently considering the onslaught of patent expiries and the current macroeconomic climate. The industry, which includes companies such as Abbott Laboratories and GlaxoSmithKline plc, continues to move products through the various stages of development, with some recently receiving FDA approval.
StockCall.com is an online platform where investors doing their due-diligence on the Drug Manufacturers - Major industry can have easy and free access to our analyst research and opinions on Abbott Laboratories and GlaxoSmithKline plc To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.
GlaxoSmithKline has had some recent success in regards to FDA approval, as it newly announced that the vaccine MenHibrix® has just been approved. The company stated that the vaccine is used to stop invasive disease caused by Neisseria meningitidis serogroups C and Y and Haemophilus influenzaetype b. Register now to have free access to our report on GlaxoSmithKline plc, and to do so please click the link below.
Abbott has also been taking strides in the drug development arena. The company recently stated that, in cooperation with Neurocrine Biosciences Inc., it is starting a phase III clinical trial to evaluate elagolix in females with endometriosis. The disease affects millions of women, and a new treatment could be valuable moving forward. Investors and shareholders of Abbott Laboratories can simply register for our complimentary reports by clicking on the link below.
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.